'In Vitro human skin testing; safety, allergy and contact sensitivity'

该项目提案建立在2010年5月授予Alcyomics的一个东北研究与发展补助金下进行的研究基础上。Alcyomics research于2010年开发了一种独特的过敏和接触敏感检测方法（Skimune™），并获得了两项英国专利（No GB No1020004.6;GB1115537.1）。我们现在需要通过将我们的结果与现有技术（包括动物模型系统（LLNA））进行比较来进一步验证该分析，并将我们的英国专利转化为国际专利。我们还将进一步验证该分析作为一种筛选试验，使用炎症细胞因子测量和t细胞增殖反应来检测多达30种化合物，我们将能够将这些化合物与皮肤外植体分析相关联，从而提高其效力。这是分析的一个新方面，并提供了有关化合物安全性的关键信息。此外，与theNIBSC合作，进一步开发用于预测治疗性单克隆抗体不良反应的检测方法。伊恩·金伯教授是皮肤致敏和毒理学方面的专家，他也将担任该项目的顾问。试点研究已证明是积极的，我们现在需要资金来开发和商业化的分析市场。

This project proposal builds on the research conducted under a One North East Grant forResearch and Development awarded to Alcyomics in May 2010. Alcyomics research in 2010developed a unique assay (Skimune™) for allergy and contact sensitivity testing with two UKPatents pending (No GB No1020004.6;GB1115537.1). We now need to further validate theassay by comparing our results with current technologies, including an animal model system(LLNA) and to convert our UK patent into an international patent s. We will also aim tofurther validate the assay as a screening test using inflammatory cytokine measurements andT cell proliferation responses for up to 30 compounds which we will be able to correlate withthe skin explant assay and therefore potency. This is a novel aspect to the assay and deliverskey information about the safety of the compounds. In addition in collaboration with theNIBSC develop the assay further for use in predicting adverse reactions to therapeuticmonoclonal antibodies. Professor Ian Kimber, expert in skin sensitisation and toxicology, willalso act as advisor/consultant to the project.Pilot studies have proved positive and we nowrequire funds to develop and commercialise the assay to market.